Evidence map›Paper›PMID 33655717›Full record

ReviewCancer reports (Hoboken, N.J.)2021

Resveratrol-loaded nanomedicines for cancer applications.

Manjusha Annaji, Ishwor Poudel, Sai H S Boddu, Robert D Arnold, Amit K Tiwari, R Jayachandra Babu

Abstract readReview
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Therapeutic Potential of Plant Phenolic Acids Combating Cancer Drug Resistance.Recent advances in food, nutrition & agriculture · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Manjusha AnnajiDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Ishwor PoudelDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Sai H S BodduDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.
Robert D ArnoldDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Amit K TiwariDepartment of Pharmacology and Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, University of Toledo, Toledo, Ohio, USA.ORCID 0000-0002-7427-7155
R Jayachandra BabuDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResveratrol (3, 5, 4 RECENT

findingsNanoparticles overcome the limitations associated with conventional chemotherapeutic drugs, such as limited availability of drugs to the tumor tissues, high systemic exposures, and consequent toxicity to healthy tissues. This review focuses on the physicochemical properties of resveratrol, the therapeutic potential of resveratrol nano-formulations, and the anticancer activity of resveratrol encapsulated nanoparticles on various malignancies such as skin, breast, prostate, colon, liver, ovarian, and lung cancers (focusing on both in vitro and in vivo studies).

conclusionsNanotechnology approaches have been extensively utilized to achieve higher solubility, improved oral bioavailability, enhanced stability, and controlled release of resveratrol. The resveratrol nanoparticles have markedly enhanced its anticancer activity both in vitro and in vivo, thus considering it as a potential strategy to fight various cancers.

Indexed as

Administration, OralAnimalsAntioxidantsBiological AvailabilityCell Line, TumorDelayed-Action PreparationsDrug CompoundingDrug StabilityHalf-LifeHumansMiceNanoparticle Drug Delivery SystemNeoplasmsResveratrolSolubilityXenograft Model Antitumor AssaysAntioxidantsDelayed-Action PreparationsNanoparticle Drug Delivery SystemResveratrolcancerin vitroin vivonanoparticlespolyphenolresveratrol

Identifiers

PMID33655717
PMCPMC8222557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.